We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EXPN:LSEExperian PLC Analysis

Data as of 2026-03-10 - not real-time

£2,791.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Experian (EXPN.L) trades at £2,791, comfortably above its 20‑day SMA (£2,626) but still below the 50‑day (£2,877) and 200‑day (£3,474) averages, signalling a short‑term pull‑back within a longer‑term downtrend. The RSI sits at 55.6, indicating neutral momentum, while the MACD histogram is positive (+40) and the signal line flags a bullish crossover, suggesting upside potential toward the nearby resistance at £2,851. Fundamentally, the company delivers 12% YoY revenue growth, a strong ROE of 27%, and margins (gross 41%, operating 25%) that outpace many peers, with a trailing PE of 25 versus an industry average of 29.5, positioning it as relatively cheap on earnings. However, the balance sheet shows a high debt‑to‑equity ratio of 105% and a modest cash buffer (£312m), raising concerns about leverage despite solid free cash flow of £1.32bn. Analysts are overwhelmingly positive (strong‑buy) with a median 12‑month target of £4,228, implying >50% upside, while the DCF model values the stock at £2,766, only slightly below the current price, and the Fear & Greed Index reflects “Extreme Greed,” hinting at heightened market optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near resistance with bearish longer‑term trend
  • Bullish MACD crossover offering limited upside
  • High 30‑day volatility (~43%) increasing short‑term risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings growth and robust margins
  • PE discount to industry and attractive forward PE of 18.4
  • Analyst consensus (strong‑buy) and >50% upside to target price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend yield (1.7%) with a 42% payout ratio
  • High ROE and consistent free cash flow supporting debt service
  • Diversified global footprint mitigating single‑region exposure

Key Metrics & Analysis

Financial Health

Revenue Growth12.20%
Profit Margin17.13%
P/E Ratio25.1
ROE26.77%
ROA9.50%
Debt/Equity105.24
P/B Ratio628.7
Op. Cash Flow£2.1B
Free Cash Flow£1.3B
Industry P/E29.5

Technical Analysis

TrendBearish
RSI55.6
Support£2,353.00
Resistance£2,851.00
MA 20£2,625.95
MA 50£2,877.40
MA 200£3,473.92
MACDBullish
VolumeStable
Fear & Greed Index77.77

Valuation

Fair Value£2,765.67
Target Price£4,215.81
Upside/Downside51.05%
GradeFair
TypeBlend
Dividend Yield1.71%

Risk Assessment

Beta0.47
Volatility43.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.